{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"Cumulative incidence rate with death as a competing risk, assessed at day 100.","groups":[{"description":"CONDITIONING REGIMEN: Patients receive cyclophosphamide IV on days -7 and -6 and busulfan IV over 3 hours on days -5 to -2.\n\nTRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplant on day 0.\n\nPOST-TRANSPLANT IMMUNOSUPPRESSION: Patients receive tacrolimus IV or PO twice daily on days -1 to 200 with taper on day 56 and methotrexate on days 1, 3, 6, and 11.\n\ncyclophosphamide: Given IV\n\nbusulfan: Given IV\n\ntacrolimus: Given IV or PO\n\nmethotrexate: Given IV\n\ncytogenetic analysis: Correlative studies\n\nflow cytometry: Correlative studies\n\npharmacological study: Correlative studies\n\npharmacogenomic studies: Correlative studies\n\nperipheral blood stem cell transplantation: Undergo PBPC transplantation\n\nallogeneic hematopoietic stem cell transplantation: Undergo allogeneic transplantation","id":"OG000","title":"Treatment (Cyclophosphamide, Busulfan, Transplant)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to day 200","title":"Non-relapse Mortality (NRM) (Patients With AML/MDS)","type":"PRIMARY","unitOfMeasure":"percent"}